An interventional study of Physical exercise prehabilitation in Obesity and Overweight, Bariatric Surgery and Prehabilitation, sponsored by Flevoziekenhuis. Terminated at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Flevoziekenhuis · Not applicable, Interventional, and Treatment
Higher dropout rate (38% versus the 10% on which the original sample size was based). Interim analysis revealed that the effect on the primary outcome measure was already highly statistically significant.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 248 studies in Obesity with a site in Netherlands — 43 open to participants now, 55 under way, 14 of them phase 3. Obesity · Netherlands.
Among the 248 studies in Obesity with a site in Netherlands, this one is the 105th largest by enrollment of the 211 interventional ones that give a count, is one of 12 that started in 2022, is one of 128 with no phase, and was the 214th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →43 of the 248 studies in Obesity with a site in Netherlands are open now. Recruiting first, the newest first:
Radboud University Medical Center · Sites in Netherlands
Ages 18+
Novo Nordisk A/S · Sites in Netherlands, United States, Belgium and 7 more countries
Ages 18+
Novo Nordisk A/S · Sites in Netherlands, Denmark
Ages 18+
Novo Nordisk A/S · Sites in Netherlands
Ages 18–65 · Healthy volunteers
Novo Nordisk A/S · Sites in Netherlands, United States, Argentina and 16 more countries
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
248 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 23 · Phase 3 38 · Phase 4 13
First in 2001; this study’s year is marked. 12 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 58 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 58 across the 211 interventional studies, 132 across the 37 observational. Of the 170 that completed or were terminated, 21 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 248 have an industry lead sponsor. The 10 most frequent:
Flevoziekenhuis is the lead sponsor of 4 studies on the registry; none are open to participants now.
Flevoziekenhuis has 2 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
19 of the studies in Obesity with a site in Netherlands that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
| NCT07463196AC Immune SAA Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants and in Participants With Cardiovascular Risk Factors | 2026-12 |
| NCT06982131Hoffmann-La RocheA Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants | 2026-12-07 |
| NCT06137261Franciscus GasthuisScreening Adults With Obesity to Reduce Heart Failure Events | 2026-12-08 |
| NCT05359887University Medical Center GroningenPET-study on the Role of the Reward System in Weight Loss After Bariatric Surgery | 2026-12-31 |
Add all 19 to your calendar (.ics) → With an account.
Among the 248 studies in Obesity with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if an exercise program before bariatric surgery works to treat obesity, could improve physical condition and weight loss before bariatric surgery and induce a lifestyle behavior change. The main questions it aims to answer are:
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in the intervention group will have two supervised training sessions per week for eight weeks in group sessions supervised by a physiotherapist.
Behavioral: Physical exercise prehabilitation
Receives no exercise prehabilitation program
Patients in the intervention group will have two supervised training sessions per week for eight weeks in group sessions supervised by a physiotherapist.
Also known as: Prehabilitation, Exercise program
six-minute walk test
Preoperative physical condition, assessed by using the six-minute walk test (6MWT). The target increase of the 6MWT is 10% in the intervention group.
Time frame: 2 months
Ran from Mar 2022 to primary completion in Jun 2026, 50 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Apr 2025 → Jun 2026 and completion May 2026 → Jun 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Higher dropout rate (38% versus the 10% on which the original sample size was based). Interim analysis revealed that the effect on the primary outcome measure was already highly statistically significant.
Higher dropout rate (38% versus the 10% on which the original sample size was based). Interim analysis revealed that the effect on the primary outcome measure was already highly statistically significant.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Flevoziekenhuis